I do like his writing, but does anyone know if he has any affiliation to CGEN or other details which may confirm his authority here. I am not disagrreeing with him and I do have a background in microbiology research and 20 years of medical practice (intensive care), but it would help to understand if he has an agenda other than information to the masses.
As Jeffrey states in his blog,in addition to being a shareholder,he is an external consultant to the company,who expresses his own opinion on the science and it's prospects, and without endorsement/approval of the company.
I can also say,pridefully,that he is my best friend of many decades,and that I know of no one that operates on a higher level of integrity.
Pat I think he makes it pretty clear in his writing regarding his association. Look at the end of his piece he always states his involvement. He is not what you would consider a true independent. Nor does he have a scientific background other then being self taught.
He writes very well and I believe is honest and sincere. Pat he has been tauting the company longer then I have. I am sincere too. But that has not gotten us into clinical trials or a commercial sale. He believes we have the real deal and certainly is closer to management. Let's see what happens. We have the holiday season in Israel now so I don't expect much in the next couple of days for sure.
For those who celebrate have a happy new year
I hope it is peaceful and for us cgen holders very prosperous as well.
I am not at my home computer, so don't have access to my old files but I think he was also a writer on ChembioDiagnostics (CEMI) a very long time ago (5+ years). I have held that company through a reverse split and am up 400% and feel it is another possible big gainer. I wasn't thinking about the holiday season, but you are right- many companies will just shutter their doors between Rosh Hashanah and Yom Yippur. I agree that clinical trials will be the recognition point for a market move. From my experience with biotechs (and I am close to many in the San Diego area and know researchers as well as company execs) the new SF location as well as the work at NWern can provide the proximity which helps in the formation of collaborations. I'm patient and have been onboard long enough. L'Shanah Tova.